- Group summary: The Yorkshire Cancer Research Early Phase Clinical Trials Centre is a Yorkshire-wide collaboration, coordinated by our team at Leeds Clinical Trials Research Unit, between clinical trialists encompassing statisticians, methodologists, laboratory scientists and clinicians.
What we do
The Yorkshire Cancer Research Early Phase Clinical Trials Centre is a Yorkshire-wide collaboration between clinical trialists encompassing statisticians, methodologists, laboratory scientists and clinicians. Working together since 2014, we have a track record of collaborative success in the delivery of early phase clinical research across a broad range of tumour sites and therapeutic interventions, and across a range of research designs (phase I, II and III trials, feasibility studies, proof of concept studies).
The Yorkshire Cancer Research Early Phase Clinical Trials Centre is co-ordinated by a team based at Leeds Clinical Trials Research Unit.
We aim to provide more opportunities for Yorkshire-based patients to participate in innovative clinical trials, enabling earlier access to novel therapies and more targetted treatments.
We are also working to:
- Increase cancer research funding into Yorkshire
- Increase collaborations with industry partners
- Develop the next generation of leading cancer researchers in Yorkshire
About Yorkshire Cancer Research
Yorkshire Cancer Research helps the people of Yorkshire avoid, survive and cope with cancer. It’s the only charity dedicated to addressing specific cancer problems in Yorkshire, by funding research projects right here in our region. The charity works to improve the prevention, diagnosis and treatment of cancer in Yorkshire so that you, your family, friends and neighbours will have the very best chance of living a long and healthy life.
It’s only by working in the heart of our communities that we will learn more about the problems that exist in Yorkshire and find solutions to tackle them.
- Use of mirtazapine in patients with chronic breathlessness: A case series.
Lovell N, Bajwah S, Maddocks M, Wilcock A, Higginson IJ.
Palliat Med. 2018 Oct;32(9):1518-1521. doi: 10.1177/0269216318787450. Epub 2018 Jul 20.
- Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study.
Oughton JB, Poad H, Twiddy M, Collinson M, Hiley V, Gordon K, Johnson M, Jain S, Noon AP, Chahal R, Simms M, Dooldeniya M, Koenig P, Goodwin L, Brown JM, Catto JWF; BRAVO study group.
BMJ Open. 2017 Aug 11;7(8):e017913. doi: 10.1136/bmjopen-2017-017913.
- Experiences of establishing an academic early phase clinical trials unit.
Brown SR, Sherratt D, Booth G, Brown J, Collinson F, Gregory W, Flanagan L.
Clin Trials. 2017 Aug;14(4):349-356. doi: 10.1177/1740774517710250. Epub 2017 May 22.
- The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection.
Snee MP, McParland L, Collinson F, Lowe CM, Striha A, Baldwin DR, Naidu B, Sebag-Montefiore D, Gregory WM, Bestall J, Hewison J, Hinsley S, Franks K.
Pilot Feasibility Stud. 2016 Feb 1;2:5. doi: 10.1186/s40814-016-0046-2. eCollection 2016. Erratum in: Pilot Feasibility Stud. 2016 Sep 12;2:55.
Who we are
Professor Julia Brown